Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan (pdf 583KB)
(WorldNews Health)

News Release January 12, 2018 Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, "Amgen Astellas") and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO: Yoshihiko Hatanaka, "Astellas") today announced the launch of Repatha® SC Injection 420 mg Auto Mini Doser (AMD), an additional dosage formulation to Repatha® SC Injection 140 mg Syringe and Pen. Repatha® is the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Japan for the treatment of patients with familial hypercholesterolemia or hypercholesterolemia who have high risk...